Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Colorectal Neoplasms 9Melanoma 5Glioblastoma 5Uterine Cervical Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Brenner Tumor 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Brain Neoplasms 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Spinal Cord Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Medulloblastoma 2Lung Neoplasms 2Glioma 2Astrocytoma 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Urethral Neoplasms 1

Interventions

Cisplatin 117Oxaliplatin 111Fluorouracil 100Capecitabine 90Docetaxel 69Leucovorin 60Irinotecan 57Paclitaxel 49S 1 (combination) 38pembrolizumab 35Trastuzumab 31Radiotherapy 25Bevacizumab 20Nivolumab 19Epirubicin 19titanium silicide 18Surgical Procedures, Operative 17Carboplatin 17Ramucirumab 16Cetuximab 15Gastrectomy 13apatinib 12Everolimus 12Gemcitabine 11Albumin-Bound Paclitaxel 10Neoadjuvant Therapy 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Stomach Neoplasms × Disulfides × Clear all
NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled
Gastrointestinal

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡